Liposarcoma

This study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…

This study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment an…

This study tests whether combining two drugs, palbociclib and INCMGA00012, is safe and effective for people with advanced liposarcoma, a rare cancer of fat cells. About 42 participants with tumors that cannot be removed by surgery or have spread will receive the combination. The …

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This early study tests an oral drug called BTX-A51 in 24 people with advanced liposarcoma (a type of fat tissue cancer) that has spread or come back. The main goal is to see if the drug is safe and tolerable at different doses. It focuses on specific genetic subtypes: MDM2-amplif…

This phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can s…

This study tests a drug called abemaciclib in 33 people with dedifferentiated liposarcoma, a rare soft tissue cancer that has spread or cannot be removed by surgery. The drug aims to slow tumor growth or shrink it by at least a quarter. Abemaciclib is not yet approved for this ca…

This phase 2 trial tests two oral drugs, ribociclib and everolimus, in people with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior treatment. The goal is to see if the combination can stop or slow tumor growth. About 48 participants will ta…

This study tests whether adding the targeted drug cabozantinib to immunotherapy (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma that has spread. About 66 adults with specific sarcoma types will take part. The goal is t…

This early-phase trial tests the safety and best dose of the chemotherapy drug eribulin when given with radiation therapy before surgery for retroperitoneal liposarcoma, a rare cancer that grows in the abdomen. About 15 patients will receive the combination to see how well they t…

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This early-phase trial tests a new immunotherapy called AGAR T cells in children with solid tumors such as liver cancer, Wilms tumor, and rhabdomyosarcoma that have returned or not responded to standard care. The cells are made from the patient's own T cells, which are geneticall…

This study tests whether combining two drugs—etrumadenant and zimberelimab—can shrink or slow advanced dedifferentiated liposarcoma that has returned, spread, or can't be removed by surgery. About 16 adults with this rare cancer will receive the treatment. The goal is to see how …

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…